Curated News
By: NewsRamp Editorial Staff
May 01, 2025
NRx Pharmaceuticals Receives $4.3M FDA Waiver for NRX-100 Ketamine Therapy
TLDR
- NRx Pharmaceuticals received a $4.3 million FDA fee waiver for NRX-100, advancing its preservative-free ketamine therapy for suicidal depression.
- NRx Pharmaceuticals plans to complete NDA by Q2 2025 for NRX-100, a single-patient ketamine formulation without benzethonium chloride.
- NRX-100 aims to offer insurance-covered treatment options for suicidal depression, enhancing access for those in need of critical care.
- NRx Pharmaceuticals' NRX-100 presents a groundbreaking approach to ketamine therapy, potentially reshaping the landscape of mental health treatment.
Impact - Why it Matters
This news matters as it highlights NRx Pharmaceuticals' progress in developing a potentially groundbreaking therapy for suicidal depression. The FDA waiver signifies a significant step towards providing innovative treatment options for patients in need, showcasing the company's commitment to addressing mental health challenges.
Summary
NRx Pharmaceuticals (NASDAQ: NRXP) received a $4.3 million FDA filing fee waiver for NRX-100, its ketamine therapy for suicidal depression. The waiver allows NRx to complete its NDA by Q2 2025 using existing resources, aiming to offer insurance-covered treatment options beyond off-label use.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NRx Pharmaceuticals Receives $4.3M FDA Waiver for NRX-100 Ketamine Therapy
